Evaxion Biotech A/S
Evaxion Biotech A/S (EVAX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EVAX · as of Sep 30, 2025
Ownership Breakdown
6
Institutional Holders
▼ 2 vs Q2
$438,176
Total Inst. Value
▲ $144,781 vs Q2
6.32M
Shares Outstanding
freeFloat 80.78%
116,537
13F Shares Held
▼ 3,218 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EVAX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 8 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
IKARIAN CAPITAL, LLC biological products, (no diagnostic substances) | 80.0K | 1.25% | 1.25% | $300.80M | Nov 14, 2025 | — held |
BOOTHBAY FUND MANAGEMENT, LLC biological products, (no diagnostic substances) | 23.7K | 37.03% | 37.03% | $89.22M | Nov 14, 2025 | — held |
RHUMBLINE ADVISERS biological products, (no diagnostic substances) | 9.4K | 14.72% | 14.72% | $35.47M | Nov 6, 2025 | — held |
GAMMA INVESTING LLC biological products, (no diagnostic substances) | 3.3K | 5.16% | 5.16% | $12.44M | Oct 2, 2025 | ▼ 184 |
SBI SECURITIES CO., LTD. biological products, (no diagnostic substances) | 65 | 0.10% | 0.10% | $244,000 | Nov 5, 2025 | ▲ 1 |
UBS GROUP AG biological products, (no diagnostic substances) | 1 | 0.00% | 0.00% | $4,000 | Nov 13, 2025 | ▼ 2.0K |
ADVISOR GROUP HOLDINGS, INC. biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 14, 2025 | EXIT |
BEACON CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Nov 7, 2025 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
1
Increased
+1 shares0
New Positions
first time holders2
Decreased
−2.2K shares2
Sold Out
fully exitedNet shares change (top 50)
2.2K
+1 / −2.2K
Net new holders
-3
0 new / 2 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EVAX insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Evaxion Biotech A/S (EVAX) is primarily owned by institutional investors, who hold approximately 1.8% of total shares outstanding. Company insiders own approximately 19.22%, while retail and public investors account for the remaining 78.93%.
The largest institutional shareholder of Evaxion Biotech A/S is IKARIAN CAPITAL, LLC, holding approximately 80,000 shares — equal to 1.25% of outstanding shares — as of September 30, 2025.
A total of 6 institutional investors currently hold EVAX stock, with a combined institutional value of approximately $438,176 as of the most recent 13F filing period.
Frequently asked questions
EVAX ownershipEvaxion Biotech A/S (EVAX) is primarily owned by institutional investors, who hold approximately 1.8% of shares. The largest shareholder is IKARIAN CAPITAL, LLC with a 1.25% stake. Company insiders hold 19.22%. Data sourced from SEC Form 13F as of September 30, 2025.